When comparing patients in the DILI and non-DILI groups in terms of patient characteristics, RIF dose, and determined PK parameters, significant differences were found solely in the median ALAT and ASAT levels (U = 240, p < 0.001; U = 240, p < 0.001) measured in the time frame from 10th to 12th day of anti-TB treatment, whereas the difference in conjugated bilirubin levels was approaching the significance threshold (U = 179, p = 0.055) (Supplementary Table S3). Here, ABCB7 is linked to tuberculosis.